Aquestive Therapeutics, Inc. Common Stock (AQST) Stock
NASDAQ · AQST
4.63
Fundamentals
Market cap
$587.39M
Price / Earnings ratio
-7.7x
Price / Sales ratio
11.2x
Price / Book ratio
-10.7x
Return on assets
-49.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Aquestive Therapeutics Q2 Earnings Call Highlights
NeutralAQSTAugust 12, 2026
MarketBeatNeutral
Aquestive Therapeutics Q2 Earnings Call Highlights
AQST

Zacks Investment Research
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
NeutralAQSTAugust 11, 2026
Zacks Investment ResearchNeutral
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
AQST

Zacks Investment Research
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
NeutralAQSTJune 24, 2026
Zacks Investment ResearchNeutral
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
AQST

MarketBeat
Aquestive Therapeutics Q1 Earnings Call Highlights
NeutralAQSTMay 14, 2026
MarketBeatNeutral
Aquestive Therapeutics Q1 Earnings Call Highlights
AQST
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesSell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy1
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
53M35M18M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
233M154M77M0
Revenue to Profit
2025$44.5M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-83.8M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
Aquestive Therapeutics Q2 Earnings Call Highlights
NeutralAQSTAugust 12, 2026
MarketBeatNeutral
Aquestive Therapeutics Q2 Earnings Call Highlights
AQST

Zacks Investment Research
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
NeutralAQSTAugust 11, 2026
Zacks Investment ResearchNeutral
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
AQST

Zacks Investment Research
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
NeutralAQSTJune 24, 2026
Zacks Investment ResearchNeutral
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
AQST

MarketBeat
Aquestive Therapeutics Q1 Earnings Call Highlights
NeutralAQSTMay 14, 2026
MarketBeatNeutral
Aquestive Therapeutics Q1 Earnings Call Highlights
AQST

Zacks Investment Research
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
NeutralAQSTMay 13, 2026
Zacks Investment ResearchNeutral
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
AQST

Zacks Investment Research
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
NeutralAQSTMay 13, 2026
Zacks Investment ResearchNeutral
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
AQST

Business Wire
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
NeutralAQSTMay 4, 2026
Business WireNeutral
AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
AQST

Zacks Investment Research
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
NeutralAQSTMay 4, 2026
Zacks Investment ResearchNeutral
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
AQST

Business Wire
Robbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc.
NeutralAQSTApril 21, 2026
Business WireNeutral
Robbins LLP Urges AQST Stockholders to Contact the Firm for Information About the Class Action Against Aquestive Therapeutics, Inc.
AQST

Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
NeutralAQSTApril 9, 2026
Zacks Investment ResearchNeutral
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
AQST
About Aquestive Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees147
CEOMr. Daniel Barber
IPO DateJul 25, 2018
HeadquartersWarren, NJ
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel Barber | CEO, President & Director | 1976 |
| Mr. A. Ernest Toth Jr. | Senior VP & CFO | 1959 |
| Ms. Lori J. Braender BSBA, Esq., J.D. | Corporate Secretary | 1956 |
| Ms. Cassie Jung | Chief Operating Officer | 1979 |
| Mr. Thomas A. Zalewski | Chief Legal Officer & Chief Compliance Officer | 1972 |
| Mr. Peter E. Boyd | Senior Vice President of Information Technology & Chief People Officer | 1966 |
| Dr. Matthew Greenhawt B.Sc., M.B.A., M.D. | Chief Medical Officer | 1974 |
| Ms. Sherry Korczynski | Chief Commercial Officer | 1970 |
| Dr. Melina T. Cioffi Pharm.D. | Senior Vice President of Regulatory Affairs | 1983 |
| Dr. Matthew William Davis M.D., R.Ph. | Chief Development Officer | 1966 |
Fundamentals
Valuation
Market cap$587.39M
Price-to-sales ratio11.19
Price-to-book value-10.69
Price-earnings ratio-7.70
Return on Equity191.00%
Return on Sales-104.00%
Return on Assets-49.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.66
Income Statement
Average volume2,536,537
EBITDA$-51.63M
1 year high (52w)$7.55
1 year low (52w)$2.93
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesSell12 Indicators
What the experts say
1 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$10.00
Est return
115.05%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.1 | +20.4 | +12.6 | -31.6 | ||||||||
| 2022 | -36.2 | -1.8 | -9.4 | -45.5 | -29.8 | -34.7 | +30.2 | +68.6 | -9.3 | -26.3 | +8.1 | -3.2 |
| 2023 | -1.1 | -11.4 | +48.1 | +26.4 | +66.2 | -28.6 | +36.0 | -26.8 | -8.4 | +12.1 | +46.1 | -15.5 |
| 2024 | +18.9 | +37.5 | +0.5 | -18.6 | -14.5 | -11.6 | +56.7 | +26.2 | +18.9 | +15.3 | -7.8 | -26.0 |
| 2025 | -17.7 | -3.1 | +9.4 | +2.4 | -9.7 | +17.8 | +12.9 | -1.3 | +46.0 | +16.0 | -4.6 | +4.2 |
| 2026 | -54.3 | -2.4 | -1.4 | -0.7 | -4.3 | +4.0 | -12.7 | +34.8 | -10.7 |



